CHMP Recommends EU Approval for Novo Nordisk's Wegovy® 7.2 mg Single-Dose Pen for Obesity

summarizeSummary

European regulators have recommended approval for a more convenient single-dose pen version of Novo Nordisk's high-dose Wegovy® (7.2 mg) for obesity, paving the way for an EU launch in Q3 2026.

check_boxKey Events

• Positive CHMP Opinion

  The Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Wegovy® 7.2 mg in a single-dose pen for people living with obesity in the EU.

• Enhanced Convenience

  This new formulation offers a more convenient, once-weekly single-dose injection, improving patient experience compared to the current multi-injection regimen for the 7.2 mg dose in the EU.

• Expected EU Launch

  Novo Nordisk anticipates launching the Wegovy® 7.2 mg single-dose pen in the EU in Q3 2026.

• Proven Efficacy

  The 7.2 mg dose demonstrated an average weight loss of 20.7% in the STEP UP trial, with approximately one-third of patients achieving 25% or greater weight loss.

auto_awesomeAnalysis

The positive opinion from the European Medicines Agency's CHMP for the single-dose pen formulation of Wegovy® 7.2 mg is a significant regulatory milestone. This approval enhances patient convenience and adherence for a key growth product in the EU market, potentially boosting sales and market penetration for Novo Nordisk's leading obesity treatment.